FDA approves once-weekly insulin icodec-abae for children with type 2 diabetes

Overview

The FDA approved insulin icodec-abae (Awiqli) as an adjunct to diet and exercise to improve glycemic control in patients aged 10 years and older with type 2 diabetes. The pediatric approval relies on adult phase 3 efficacy and safety findings and a single-dose pharmacokinetic study in 18 pediatric patients, rather than a separate randomized efficacy trial in children.

Background

Basal insulin is used in the management of youth-onset type 2 diabetes. Insulin icodec-abae (Awiqli) is a long-acting insulin analog administered subcutaneously once weekly using a prefilled pen. The FDA previously approved it for adults with type 2 diabetes.

Data Highlights

Key Findings

• The FDA approved insulin icodec-abae for patients aged 10 years and older with type 2 diabetes as an adjunct to diet and exercise.
• The pediatric approval was supported by adult ONWARDS phase 3 findings and a single-dose pharmacokinetic study in 18 pediatric patients; no separate randomized efficacy trial in children supported the approval.
• Although initial-dose absorption was faster in pediatric patients than in adults, pharmacometric modeling indicated comparable insulin levels after several doses, and the FDA expects similar glucose-lowering effects.
• The FDA describes the safety profile as similar to that of other insulin products. Severe hypoglycemia can cause seizures, loss of consciousness, life-threatening complications, or death.
• Additional warnings include medication errors, accidental overdose, hyperglycemia, hypokalemia, and fluid retention or heart failure when used with thiazolidinediones.
• The FDA advises clinicians to ensure patients and caregivers understand dose selection and administration, check the pen dose counter before each injection, and not withdraw insulin from the pen with a syringe; dosing should be individualized and glucose monitored closely during initiation or transitions from daily basal insulin.

Clinical Implications

The weekly formulation changes the dosing frequency and concentration relative to conventional insulin regimens, so the FDA emphasizes patient and caregiver understanding of pen use and dose selection. Dosing should be individualized using glucose monitoring, metabolic requirements, and glycemic goals, with close monitoring during treatment initiation or transition from daily basal insulin.

Conclusion

The FDA’s pediatric approval extends once-weekly insulin icodec-abae to patients aged 10 years and older with type 2 diabetes. Its pediatric evidence base combines adult trial findings with pharmacokinetic data from a small pediatric study, alongside FDA warnings and administration precautions.

Related Resources & Content

1. U.S. Food and Drug Administration, FDA, 2026 — FDA Approves First Once-Weekly Insulin for Type 2 Diabetes Mellitus in Pediatric Patients
2. ISPAD, ISPAD Clinical Practice Consensus Guidelines, 2024 — Type 2 Diabetes in Children and Adolescents
3. MDSpire News, MDSpire News, n.d. — FDA Approval Advances Basal Insulin
4. MDSpire News, MDSpire News, n.d. — Once-Weekly Insulin Effective and Safe Alternative to Daily Dosing
5. mdspire news — FDA approves once-weekly insulin for type 2 diabetes
6. MDSpire News — FDA Panel Votes Against Weekly Insulin for T1D
7. FDA Approves First Once-Weekly Insulin for Type 2 Diabetes Mellitus in Pediatric Patients
8. ISPAD Clinical Practice Consensus Guidelines 2024: Type 2 Diabetes in Children and Adolescents
9. FDA Approval Advances Basal Insulin
10. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin | New England Journal of Medicine